Page last updated: 2024-11-07

pilocarpine and Miosis

pilocarpine has been researched along with Miosis in 28 studies

Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
(+)-pilocarpine : The (+)-enantiomer of pilocarpine.

Miosis: Pupillary constriction. This may result from congenital absence of the dilatator pupillary muscle, defective sympathetic innervation, or irritation of the CONJUNCTIVA or CORNEA.

Research Excerpts

ExcerptRelevanceReference
"To assess changes in intraocular pressure (IOP) and pupil diameter (PD) induced by daily application of an unfixed combination of latanoprost and pilocarpine in normal dogs."9.16Effects of an unfixed combination of latanoprost and pilocarpine on the intraocular pressure and pupil size of normal dogs. ( Abbasi, N; Gholipour, MA; Sarchahi, AA, 2012)
"Lower response of aqueous outflow pathway structures after pilocarpine could be observed in primary open angle glaucoma (POAG) patients, which is likely to be helpful for understanding intraocular pressure (IOP) evaluation in glaucoma."8.31Changes to Outflow Structures After Pilocarpine in Primary Open Angle Glaucoma Compared With Healthy Individuals Using Optical Coherence Tomography. ( Chen, L; Chen, W; Chen, Z; Deng, C; Wang, J; Zhang, H, 2023)
"To investigate the mechanism by which pilocarpine causes increased aqueous humor (AH) flare, hypotony, and miosis in dogs."7.70Inhibition of pilocarpine-induced aqueous humor flare, hypotony, and miosis by topical administration of anti-inflammatory and anesthetic drugs to dogs. ( Gionfriddo, J; Krohne, SG; Morrison, EA, 1998)
"Instillation of pilocarpine-induced a miosis in a rabbit."7.68Inhibitory effect of pilocarpine on norepinephrine release from electrically stimulated iris dilator muscles of rabbits as a most possible mechanism of pilocarpine-induced miosis. ( Kokubu, N; Shiraishi, K; Takayanagi, I, 1993)
"This work comparatively studies the effects of dihydroergocristine, timolol and pilocarpine on intraocular pressure and pupil diameter in conscious rabbits."7.68Effects of topical dihydroergocristine on intraocular pressure, aqueous humor dynamics and pupil diameter in conscious rabbits. A comparative study with timolol and pilocarpine. ( Garrido García, M; Pablo Martínez, V; Santafé Oroz, J; Segarra Domenech, J, 1991)
"Effects of topical administration of a single dose of 2% pilocarpine on intraocular pressure (IOP) and pupil diameter were evaluated in normotensive eyes of 10 clinically normal cats over 12 hours."7.68Effects of topical administration of 2.0% pilocarpine on intraocular pressure and pupil size in cats. ( Latimer, CA; Wilkie, DA, 1991)
"To assess changes in intraocular pressure (IOP) and pupil diameter (PD) induced by daily application of an unfixed combination of latanoprost and pilocarpine in normal dogs."5.16Effects of an unfixed combination of latanoprost and pilocarpine on the intraocular pressure and pupil size of normal dogs. ( Abbasi, N; Gholipour, MA; Sarchahi, AA, 2012)
"5% were evaluated by comparing the effects of two drugs given together and alone on the reversal of mydriasis induced by tropicamide (0."5.08The additive miotic effects of dapiprazole and pilocarpine. ( Geyer, O; Lazar, M; Loewenstein, A; Neudorfer, M; Shalmon, B, 1995)
"To determine if pilocarpine 4% produces miosis when delivered via a spray, eleven eyes of ten patients undergoing a laser peripheral iridotomy for occludable angles were pretreated with one application of pilocarpine spray to closed eyelids."5.08Pilocarpine spray: an alternative delivery method. ( Campagna, JA; Doe, EA, 1998)
"Lower response of aqueous outflow pathway structures after pilocarpine could be observed in primary open angle glaucoma (POAG) patients, which is likely to be helpful for understanding intraocular pressure (IOP) evaluation in glaucoma."4.31Changes to Outflow Structures After Pilocarpine in Primary Open Angle Glaucoma Compared With Healthy Individuals Using Optical Coherence Tomography. ( Chen, L; Chen, W; Chen, Z; Deng, C; Wang, J; Zhang, H, 2023)
" Following pilocarpine-induced miosis, lens thickness (LT) increased and anterior chamber depth (ACD) decreased (all groups p < 0."4.31Influence of miosis and laser peripheral iridotomy on intraocular lens power calculation in patients with primary angle closure disease. ( Chan, G; Chen, Y; Qian, D; Sun, X; Wang, J; Yang, H, 2023)
"To investigate the mechanism by which pilocarpine causes increased aqueous humor (AH) flare, hypotony, and miosis in dogs."3.70Inhibition of pilocarpine-induced aqueous humor flare, hypotony, and miosis by topical administration of anti-inflammatory and anesthetic drugs to dogs. ( Gionfriddo, J; Krohne, SG; Morrison, EA, 1998)
" This study was performed to assess the in vivo performance of these two formulations using miosis in the albino rabbit eye produced by PHCL as a measure of ocular bioavailability."3.70Evaluation of pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model. ( Blanchard, J; Desai, SD, 1998)
" Ocular hypertension in the rabbit was induced by alpha-chymotrypsin or by water loading."3.70Pharmacological profile of a new topical pilocarpine formulation. ( Bucolo, C; Mangiafico, P, 1999)
"Instillation of pilocarpine-induced a miosis in a rabbit."3.68Inhibitory effect of pilocarpine on norepinephrine release from electrically stimulated iris dilator muscles of rabbits as a most possible mechanism of pilocarpine-induced miosis. ( Kokubu, N; Shiraishi, K; Takayanagi, I, 1993)
"This work comparatively studies the effects of dihydroergocristine, timolol and pilocarpine on intraocular pressure and pupil diameter in conscious rabbits."3.68Effects of topical dihydroergocristine on intraocular pressure, aqueous humor dynamics and pupil diameter in conscious rabbits. A comparative study with timolol and pilocarpine. ( Garrido García, M; Pablo Martínez, V; Santafé Oroz, J; Segarra Domenech, J, 1991)
"Effects of topical administration of a single dose of 2% pilocarpine on intraocular pressure (IOP) and pupil diameter were evaluated in normotensive eyes of 10 clinically normal cats over 12 hours."3.68Effects of topical administration of 2.0% pilocarpine on intraocular pressure and pupil size in cats. ( Latimer, CA; Wilkie, DA, 1991)
" In this study, the degree of intraocular penetration of topical fluorescein was compared with the degree of pilocarpine-induced miosis in six tonic pupils and in seven age-matched normal controls."3.68Corneal permeability in patients with tonic pupil. A reevaluation of its cholinergic supersensitivity. ( Utsumi, T, 1990)
"Pilocarpine is a well established topical agent, but suffers troublesome sequelae, the most apparent of which is pupillary constriction."1.29The effect of pilocarpine on the glaucomatous visual field. ( Canning, CR; Elkington, AR; Luff, AJ; Webster, AR, 1993)
" In human studies, the 1 action is prolonged and the intensity is increased by PAS-F and Carbopol containing preparations compared with aqueous 1 solution (relative bioavailability about 200%; the duration of the intraocular pressure is 4."1.28[Antiglaucoma ophthalmic agents with prolonged action based on macromolecular excipients. 2. In vivo studies]. ( Keipert, S; Klatt, A; Pergande, G, 1990)

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19901 (3.57)18.7374
1990's17 (60.71)18.2507
2000's2 (7.14)29.6817
2010's2 (7.14)24.3611
2020's6 (21.43)2.80

Authors

AuthorsStudies
Westheimer, G1
Chen, L1
Chen, Z1
Deng, C1
Chen, W1
Zhang, H1
Wang, J2
Yang, H1
Qian, D1
Chan, G1
Sun, X1
Chen, Y1
Cheng, M1
Liu, S1
Chen, X1
Zhou, X2
Wang, X1
Kinney, M1
Johnson, AD1
Reddix, M1
McCann, MB1
Rashidi, N1
Pant, AD1
Salinas, SD1
Shah, M1
Thomas, VS1
Zhang, G1
Dorairaj, S1
Amini, R1
Park, S1
Kang, S1
Lim, J1
Park, E1
Nam, T1
Jeong, S1
Seo, K1
Kwon, HJ1
Kim, HY1
Sarchahi, AA1
Abbasi, N1
Gholipour, MA1
SPIECKER, HD1
Hanyu, H1
Hirao, K1
Shimizu, S1
Kanetaka, H1
Sakurai, H1
Iwamoto, T1
Geyer, O1
Loewenstein, A1
Shalmon, B1
Neudorfer, M1
Lazar, M1
Suhonen, P1
Järvinen, T2
Lehmussaari, K1
Reunamäki, T1
Urtti, A2
Smith, EM1
Buyukmihci, NC1
Farver, TB1
Webster, AR1
Luff, AJ1
Canning, CR1
Elkington, AR1
Takayanagi, I1
Kokubu, N1
Shiraishi, K1
Jarho, P1
Järvinen, K1
Stella, VJ1
Kushnick, H1
Liebmann, JM1
Ritch, R1
Doe, EA1
Campagna, JA1
Krohne, SG1
Gionfriddo, J1
Morrison, EA1
Desai, SD1
Blanchard, J1
Bucolo, C1
Mangiafico, P1
Gabelt, BT1
Kaufman, PL1
Santafé Oroz, J1
Segarra Domenech, J1
Garrido García, M1
Pablo Martínez, V1
Wilkie, DA1
Latimer, CA1
Pergande, G1
Keipert, S2
Klatt, A1
Siebenbrodt, I1
Utsumi, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Participants With Presbyopia[NCT03804268]Phase 3323 participants (Actual)Interventional2018-12-21Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Mesopic, High-contrast, Binocular DCNVA Letters at Day 30, Hour 0.25

Visual acuity for near (40 cm) target was measured in mesopic conditions. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. MMRM was used for analyses. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 0.25)

Interventionletters correctly read (Least Squares Mean)
Vehicle3.7
Pilocarpine HCl Ophthalmic Solution6.3

Change From Baseline in Mesopic, High-contrast, Binocular DCNVA Letters at Day 30, Hour 0.5

Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. Mixed effect model for repeated measures (MMRM) was used for analyses. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 0.5)

Interventionletters read correctly (Least Squares Mean)
Vehicle4.2
Pilocarpine HCl Ophthalmic Solution9.3

Change From Baseline in Photopic, High-contrast, Binocular Distance-corrected Intermediate Visual Acuity (DCIVA) Letters at Day 30, Hour 3

Visual acuity for intermediate (66 cm) target was measured in photopic conditions using an eye chart. Photopic condition was defined as high lighting ≥80 cd/m^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. MMRM was used for analyses. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)

Interventionletters read correctly (Least Squares Mean)
Vehicle3.1
Pilocarpine HCl Ophthalmic Solution6.6

Mean Change From Baseline in Mesopic Near Vision Presbyopia Task-based Questionnaire (NVPTQ) Performance Score at Day 30, Hour 3

NVPTQ had 12 questions on 4 reading tasks(reading a paragraph from book, excerpts from an article in newspaper, portion of a nutrition label, and a section from restaurant menu). Participants completed specific reading tasks under mesopic conditions without any near-vision correction and answered 3 questions for each task, rating their vision-related reading ability as 0=I could not read any text due to problems seeing up close,1=poor,2=fair,3=good,4=very good,5=excellent;impact of squinting on performance as 0=No,I did not squint, 1=Yes,squinting helped me read some/all text, 2=Yes,but I still could not read any of the text; and satisfaction as 0=very dissatisfied to 4=very satisfied. The score based on vision related ability and impact of squinting=(Book testlet+Newspaper testlet+Menu testlet+Nutrition Label testlet)/(testlets with non-missing responses), total possible score of 0-5. Higher scores=better outcomes;positive change from Baseline=improved performance(reading ability). (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)

Interventionscore on a scale (Least Squares Mean)
Vehicle0.6
Pilocarpine HCl Ophthalmic Solution1.4

Mean Change From Baseline in Mesopic NVPTQ Satisfaction Score at Day 30, Hour 3

NVPTQ had 12 questions on 4 reading tasks(reading a paragraph from book, excerpts from an article in newspaper, portion of a nutrition label, and a section from restaurant menu). Participants completed specific reading tasks under mesopic conditions without any near-vision correction and answered 3 questions for each task, rating their vision-related reading ability as 0=I could not read any text due to problems seeing up close to 5=excellent; impact of squinting on performance as 0=No, I did not squint, 1=Yes, squinting helped me read some/all text, 2=Yes, but I still could not read any of the text; and satisfaction as 0=very dissatisfied,1=dissatisfied,2=neither satisfied nor dissatisfied,3=satisfied, 4=very satisfied. The score based on satisfaction items=(Book testlet+Newspaper testlet+Menu testlet+Nutrition Label testlet)/(testlets with non-missing responses) for a total possible score of 0 to 4. Higher scores=better outcomes; a positive change from Baseline=higher satisfaction. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)

Interventionscore on a scale (Least Squares Mean)
Vehicle0.6
Pilocarpine HCl Ophthalmic Solution1.4

Mean Change From Baseline in PICQ Impact Score at Day 30, Hour 3

PICQ had 20 questions about impact experienced by participants due to their problems seeing up over past 7 days. PICQ Impact domain had 6 items: Item 9:Rely on others,15:rest eyes,16:Feel older,17:Feel self-conscious,19:Take longer to complete a task,20:Inconvenient. First 5 impacts items included response categories: 0=never to 4=all the time. Item 20 had response categories: 0=not at all to 4=extremely. Item 9 included an additional response category with a value of 9 to indicate question was not applicable to participant and the responses were assigned missing values. PICQ Impacts Score=[(Item9+Item15+Items16,17Testlet+Item19+Item20)/(nonmissing responses to 5 components of impacts score)] where Items 16,17 Testlet=(Item16+Item17)/non-missing responses to Items 16 and 17. PICQ Impact score ranges from 0 to 4; with 0=least amount of impacts to 4=greatest amount of impacts. Higher scores correspond to poorer outcomes. A negative change from Baseline=improvement. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)

Interventionscore on a scale (Least Squares Mean)
Vehicle-0.4
Pilocarpine HCl Ophthalmic Solution-0.7

Mean Change From Baseline in Presbyopia Impact and Coping Questionnaire (PICQ) Coping Score at Day 30, Hour 3

PICQ=20 questions about impact experienced by participants due to their problems over past 7 days.PICQ Coping domain had 8 items: 1:Normal-sized text,2:Small-sized text,3:Information on a computer,4:Information on a cell phone,5:Increase font size,6:Use glasses to read close,12:Hold reading materials farther out/closer,13:Squint to read. Each item had response categories:0=never to 4=all the time. Items 3, 4, 5, and 6 had additional response categories with values of 9/10 to indicate the question is not applicable to participant and were assigned missing values.PICQ Coping Score:(Item 1,2 Testlet+Item 3,4 Testlet+Item 5+Item 6+Item 12+Item 13)/non-missing responses to the 6 components of coping score where Items 1,2 Testlet=(Item1+Item2)/non-missing responses to Items 1,2;Items 3,4 Testlet=(Item3+Item4)/non-missing responses to Items 3, 4. Score ranges:0=to least amount of coping to 4=greatest amount of coping. Higher scores=poorer outcome; a negative change from Baseline=improvement. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)

Interventionscore on a scale (Least Squares Mean)
Vehicle-0.5
Pilocarpine HCl Ophthalmic Solution-1.0

Percentage of Participants Achieving 20/40 or Better in Photopic, High-contrast, Binocular, DCNVA at Day 30, Hour 1

Visual acuity for near (40 cm) target was measured in photopic conditions using an eye chart. Photopic condition was defined as high lighting ≥80 cd/m^2 measured at the target. Percentage of participants achieving 20/40 or better in photopic, high-contrast, binocular, DCNVA are reported. (NCT03804268)
Timeframe: Day 30 (Hour 1)

Interventionpercentage of participants (Number)
Vehicle73.9
Pilocarpine HCl Ophthalmic Solution92.5

Percentage of Participants Achieving 20/40 or Better in Photopic, High-contrast, Binocular, DCNVA at Day 30, Hour 3

Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Photopic condition was defined as high lighting ≥80 cd/m^2 measured at the target. Percentage of participants achieving 20/40 or better in photopic, high-contrast, binocular, DCNVA are reported. (NCT03804268)
Timeframe: Day 30 (Hour 3)

Interventionpercentage of participants (Number)
Vehicle71.9
Pilocarpine HCl Ophthalmic Solution84.5

Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 3

Visual acuity for near (40 centimeters (cm)) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter (cd/m^2) measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 3)

Interventionpercentage of participants (Number)
Vehicle8.1
Pilocarpine HCl Ophthalmic Solution30.7

Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 6

Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 6)

Interventionpercentage of participants (Number)
Vehicle8.8
Pilocarpine HCl Ophthalmic Solution18.4

Percentage of Participants Gaining 3-lines or More in Mesopic, High-contrast, Binocular, DCNVA at Day 30, Hour 10

Visual acuity for near (40cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m^2measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast, binocular DCNVA are reported. (NCT03804268)
Timeframe: Baseline (Day1) to Day 30 (Hour 10)

Interventionpercentage of participants (Number)
Vehicle8.6
Pilocarpine HCl Ophthalmic Solution7.5

Percentage of Participants Gaining 3-lines or More in Mesopic, High-contrast, Binocular, DCNVA at Day 30, Hour 8

Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported. (NCT03804268)
Timeframe: Baseline (Day 1) to Day 30 (Hour 8)

Interventionpercentage of participants (Number)
Vehicle8.5
Pilocarpine HCl Ophthalmic Solution10.6

Trials

3 trials available for pilocarpine and Miosis

ArticleYear
Effects of an unfixed combination of latanoprost and pilocarpine on the intraocular pressure and pupil size of normal dogs.
    Veterinary ophthalmology, 2012, Volume: 15 Suppl 1

    Topics: Animals; Antihypertensive Agents; Conjunctiva; Dogs; Drug Therapy, Combination; Female; Intraocular

2012
The additive miotic effects of dapiprazole and pilocarpine.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 1995, Volume: 233, Issue:7

    Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug

1995
Pilocarpine spray: an alternative delivery method.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 1998, Volume: 14, Issue:1

    Topics: Aerosols; Humans; Miosis; Miotics; Nebulizers and Vaporizers; Pilocarpine; Pupil

1998

Other Studies

25 other studies available for pilocarpine and Miosis

ArticleYear
Topical Review: Pilocarpine-induced Miosis as Help for Early Presbyopes?
    Optometry and vision science : official publication of the American Academy of Optometry, 2022, 08-01, Volume: 99, Issue:8

    Topics: Accommodation, Ocular; Humans; Miosis; Ophthalmic Solutions; Pilocarpine; Presbyopia; Pupil

2022
Changes to Outflow Structures After Pilocarpine in Primary Open Angle Glaucoma Compared With Healthy Individuals Using Optical Coherence Tomography.
    Journal of glaucoma, 2023, 07-01, Volume: 32, Issue:7

    Topics: Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Miosis; Pilocarpine; Tomography, Optic

2023
Influence of miosis and laser peripheral iridotomy on intraocular lens power calculation in patients with primary angle closure disease.
    Eye (London, England), 2023, Volume: 37, Issue:13

    Topics: Biometry; Glaucoma, Angle-Closure; Humans; Intraocular Pressure; Iridectomy; Iris; Lasers; Lenses, I

2023
Pharmacological Accommodative Changes of the Anterior Segment and Its Impact on the Vault in Implantable Collamer Lens Implantation.
    Journal of refractive surgery (Thorofare, N.J. : 1995), 2023, Volume: 39, Issue:6

    Topics: Adult; Humans; Lenses, Intraocular; Miosis; Mydriasis; Pilocarpine; Tropicamide

2023
Temporal Effects of 2% Pilocarpine Ophthalmic Solution on Human Pupil Size and Accommodation.
    Military medicine, 2020, 01-07, Volume: 185, Issue:Suppl 1

    Topics: Accommodation, Ocular; Adolescent; Adult; Female; Humans; Male; Miosis; Nerve Agents; Ophthalmic Sol

2020
Iris stromal cell nuclei deform to more elongated shapes during pharmacologically-induced miosis and mydriasis.
    Experimental eye research, 2021, Volume: 202

    Topics: Animals; Disease Models, Animal; Drug Combinations; Iris; Microscopy, Confocal; Miosis; Miotics; Myd

2021
Effects of prostaglandin-mediated and cholinergic-mediated miosis on morphology of the ciliary cleft region in dogs.
    American journal of veterinary research, 2018, Volume: 79, Issue:9

    Topics: Animals; Antihypertensive Agents; Cholinergic Agents; Cross-Over Studies; Dogs; Eye; Intraocular Pre

2018
A pharmacologic pupillary test in the diagnosis of diabetic autonomic neuropathy.
    Korean journal of ophthalmology : KJO, 2009, Volume: 23, Issue:4

    Topics: Adrenergic alpha-Agonists; Adult; Aged; Clonidine; Diabetic Nephropathies; Diagnosis, Differential;

2009
[STUDIES ON DRIVING ABILITY FOLLOWING MEDICAL MYDRIASIS AND MIOSIS].
    Bericht uber die Zusammenkunft. Deutsche Ophthalmologische Gesellschaft, 1964, Volume: 65

    Topics: Accidents; Accidents, Traffic; Atropine; Automobile Driving; Humans; Miosis; Miotics; Mydriasis; Myd

1964
Phenylephrine and pilocarpine eye drop test for dementia with Lewy bodies and Alzheimer's disease.
    Neuroscience letters, 2007, Mar-06, Volume: 414, Issue:2

    Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Diagnosis, Differential; Female;

2007
Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in the eyedrop.
    Pharmaceutical research, 1995, Volume: 12, Issue:4

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Absorption; Animals; beta-Cyclodextrins; Biological Availability;

1995
Effect of topical pilocarpine treatment on tear production in dogs.
    Journal of the American Veterinary Medical Association, 1994, Nov-01, Volume: 205, Issue:9

    Topics: Animals; Blepharospasm; Circadian Rhythm; Conjunctiva; Dog Diseases; Dogs; Female; Hyperemia; Kerato

1994
The effect of pilocarpine on the glaucomatous visual field.
    The British journal of ophthalmology, 1993, Volume: 77, Issue:11

    Topics: Aged; Aged, 80 and over; Chronic Disease; Female; Glaucoma, Open-Angle; Humans; Male; Middle Aged; M

1993
Inhibitory effect of pilocarpine on norepinephrine release from electrically stimulated iris dilator muscles of rabbits as a most possible mechanism of pilocarpine-induced miosis.
    Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi, 1993, Volume: 29, Issue:2

    Topics: Animals; Atropine; Depression, Chemical; Dose-Response Relationship, Drug; Electric Stimulation; In

1993
Modified beta-cyclodextrin (SBE7-beta-CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits.
    The Journal of pharmacy and pharmacology, 1996, Volume: 48, Issue:3

    Topics: Animals; beta-Cyclodextrins; Cyclodextrins; Drug Tolerance; Eye; Miosis; Pharmaceutical Vehicles; Pi

1996
Systemic pilocarpine toxicity from Ocusert leakage.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1996, Volume: 114, Issue:11

    Topics: Adolescent; Dizziness; Drug Delivery Systems; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ma

1996
Inhibition of pilocarpine-induced aqueous humor flare, hypotony, and miosis by topical administration of anti-inflammatory and anesthetic drugs to dogs.
    American journal of veterinary research, 1998, Volume: 59, Issue:4

    Topics: Administration, Topical; Anesthetics, Local; Animals; Anti-Inflammatory Agents; Aqueous Humor; Diclo

1998
Evaluation of pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model.
    Journal of pharmaceutical sciences, 1998, Volume: 87, Issue:10

    Topics: Animals; Area Under Curve; Biological Availability; Delayed-Action Preparations; Drug Carriers; Drug

1998
Pharmacological profile of a new topical pilocarpine formulation.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 1999, Volume: 15, Issue:6

    Topics: Animals; Biological Availability; Chymotrypsin; Hyaluronic Acid; Kinetics; Miosis; Ocular Hypertensi

1999
Inhibition of outflow facility and accommodative and miotic responses to pilocarpine in rhesus monkeys by muscarinic receptor subtype antagonists.
    The Journal of pharmacology and experimental therapeutics, 1992, Volume: 263, Issue:3

    Topics: Accommodation, Ocular; Animals; Aqueous Humor; Female; Intraocular Pressure; Macaca mulatta; Male; M

1992
Effects of topical dihydroergocristine on intraocular pressure, aqueous humor dynamics and pupil diameter in conscious rabbits. A comparative study with timolol and pilocarpine.
    Methods and findings in experimental and clinical pharmacology, 1991, Volume: 13, Issue:4

    Topics: Administration, Topical; Animals; Aqueous Humor; Consciousness; Dihydroergotoxine; Intraocular Press

1991
Effects of topical administration of 2.0% pilocarpine on intraocular pressure and pupil size in cats.
    American journal of veterinary research, 1991, Volume: 52, Issue:3

    Topics: Administration, Topical; Animals; Cat Diseases; Cats; Female; Intraocular Pressure; Male; Miosis; Pi

1991
[Antiglaucoma ophthalmic agents with prolonged action based on macromolecular excipients. 2. In vivo studies].
    Die Pharmazie, 1990, Volume: 45, Issue:8

    Topics: Acrylic Resins; Animals; Biological Availability; Delayed-Action Preparations; Excipients; Female; G

1990
[Antiglaucoma ophthalmic agents with prolonged action with based on macromolecular excipients. 3. Optimized drop preparation on a polyacrylate base].
    Die Pharmazie, 1990, Volume: 45, Issue:8

    Topics: Acrylic Resins; Carbachol; Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Delay

1990
Corneal permeability in patients with tonic pupil. A reevaluation of its cholinergic supersensitivity.
    Journal of clinical neuro-ophthalmology, 1990, Volume: 10, Issue:1

    Topics: Adult; Anterior Chamber; Cornea; Female; Fluorescein; Fluoresceins; Fluorophotometry; Humans; Male;

1990